CA2710388A1 - Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars - Google Patents

Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars Download PDF

Info

Publication number
CA2710388A1
CA2710388A1 CA2710388A CA2710388A CA2710388A1 CA 2710388 A1 CA2710388 A1 CA 2710388A1 CA 2710388 A CA2710388 A CA 2710388A CA 2710388 A CA2710388 A CA 2710388A CA 2710388 A1 CA2710388 A1 CA 2710388A1
Authority
CA
Canada
Prior art keywords
connexin
polynucleotide
scar
abnormal
scars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2710388A
Other languages
English (en)
French (fr)
Inventor
David L. Becker
Colin R. Green
Bradford J. Duft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2710388A1 publication Critical patent/CA2710388A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
CA2710388A 2007-12-21 2008-12-22 Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars Abandoned CA2710388A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US887707P 2007-12-21 2007-12-21
US61/008,877 2007-12-21
PCT/US2008/014028 WO2009085277A2 (en) 2007-12-21 2008-12-22 Treatment of abnormal or excessive scars

Publications (1)

Publication Number Publication Date
CA2710388A1 true CA2710388A1 (en) 2009-07-09

Family

ID=40824960

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2710388A Abandoned CA2710388A1 (en) 2007-12-21 2008-12-22 Use of anti-connexin polynucleotides for the treatment of abnormal or excessive scars

Country Status (7)

Country Link
US (1) US20110130710A1 (cg-RX-API-DMAC10.html)
EP (1) EP2252690A2 (cg-RX-API-DMAC10.html)
JP (2) JP2011507862A (cg-RX-API-DMAC10.html)
AU (1) AU2008343758A1 (cg-RX-API-DMAC10.html)
CA (1) CA2710388A1 (cg-RX-API-DMAC10.html)
WO (1) WO2009085277A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA201005223B (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
CN102920996A (zh) * 2007-12-11 2013-02-13 科达治疗公司 受损伤口愈合的药物组合物
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
MX351881B (es) 2012-03-01 2017-11-01 Firststring Res Inc Geles tópicos que contienen péptidos de alfa-conexina c- terminal (act).
US20180126033A9 (en) 2012-03-14 2018-05-10 MAM Holdings of West Florida, L.L.C. Collagen compositions and uses for biomaterial implants
US10576037B2 (en) * 2012-03-14 2020-03-03 MAM Holdings of West Florida, L.L.C. Compositions comprising placental collagen for use in wound healing
JP2015513905A (ja) 2012-03-27 2015-05-18 コーダ セラピューティクス， インコーポレイテッド カドヘリン調節に基づく組成物および処置
US20140072613A1 (en) * 2012-09-10 2014-03-13 Cynthia Lander Compositions and Methods for Treating Cutaneous Scarring
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
WO2016140921A1 (en) 2015-03-02 2016-09-09 180 Therapeutics Lp Method of treating a localized fibrotic disorder using an il-33 antagonist
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
WO2019005643A1 (en) * 2017-06-26 2019-01-03 Next Science IP Holdings Pty Ltd METHOD OF TREATING PATHOLOGIES OF COLLAGEN FIBERS
WO2019152110A1 (en) * 2018-01-31 2019-08-08 Kci Usa, Inc. Antimicrobial composition, dressing, dressing components, and method
US12138293B2 (en) 2020-10-22 2024-11-12 Xequel Bio, Inc. Peptide formulations and ophthalmic uses thereof
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1322714C (en) * 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
US6566339B1 (en) * 1995-08-04 2003-05-20 Renovo Limited Pharmaceutical composition
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
AU7248896A (en) * 1995-10-11 1997-04-30 Chiron Corporation Combination pdgf, kgf, igf and igfbp for wound healing
IT1294967B1 (it) * 1996-10-09 1999-04-23 Ist Farmacoterapico It Spa Composizione immunogenica da tlp
AU7180498A (en) * 1996-11-15 1998-06-03 University Of Massachusetts Huntingtin-related therapeutics and bioassay
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
US5965618A (en) * 1997-11-17 1999-10-12 Perricone; Nicholas V. Treatment of scar tissue using lipoic acid
US6855505B2 (en) * 1998-06-26 2005-02-15 Renovo Limited Method for quantifying TGF-β
US7098190B1 (en) * 1999-01-27 2006-08-29 Coda Therapeutics Ltd. Formulations comprising antisense nucleotides to connexins
GB9903598D0 (en) * 1999-02-18 1999-04-07 Univ Manchester Connective tissue healing
US7229822B1 (en) * 2000-02-29 2007-06-12 Univ Columbia Melanoma differentation associated gene-5 and vectors and cells containing same
US7186802B2 (en) * 2000-08-15 2007-03-06 Immunex Corporation Claudin polypeptides
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
DE602004013439T2 (de) * 2003-06-09 2009-06-04 Ascend Therapeutics, Inc. Behandlung und prävention von übermässiger narbenbildung mit 4-hydroxy tamoxifen
CN1922320B (zh) * 2003-12-03 2013-04-24 科达治疗（新西兰）有限公司 靶向连接蛋白的反义化合物及其使用方法
JP5097891B2 (ja) * 2005-09-20 2012-12-12 株式会社ポーラファルマ 皮膚外用剤
RU2542471C2 (ru) * 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
EP2342340A1 (en) * 2008-09-22 2011-07-13 Rxi Pharmaceuticals Corporation Rna interference in skin indications

Also Published As

Publication number Publication date
JP2015057431A (ja) 2015-03-26
WO2009085277A3 (en) 2009-11-26
US20110130710A1 (en) 2011-06-02
JP2011507862A (ja) 2011-03-10
ZA201005223B (en) 2011-09-28
EP2252690A2 (en) 2010-11-24
WO2009085277A2 (en) 2009-07-09
AU2008343758A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
US20110130710A1 (en) Treatment of abnormal or excessive scars
US9738892B2 (en) Treatment of fibrotic conditions
CN103520197B (zh) 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
JP2015057430A (ja) 異常瘢痕または過剰瘢痕の治療のための抗コネキシンポリヌクレオチドおよび抗コネキシンペプチドの使用
JP2018177823A (ja) 創傷治癒のための改善された方法および組成物
US20110144182A1 (en) Treatment of surgical adhesions
JP2014144976A (ja) 損傷した創傷治癒組成物および治療
JP2015083606A (ja) 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
AU2015201309A1 (en) Treatment of fibrotic conditions
AU2017200710A1 (en) Treatment of fibrotic conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131220

FZDE Dead

Effective date: 20180523